[{"address1": "Gooimeer 2-35", "city": "Naarden", "zip": "1411 DC", "country": "Netherlands", "phone": "31 35 206 2971", "website": "https://www.newamsterdampharma.com", "industry": "", "industryKey": "", "sector": "", "sectorKey": "", "longBusinessSummary": "NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Michael Harvey Davidson FACC, Facp., M.D.", "age": 69, "title": "CEO, President & Executive Director", "yearBorn": 1956, "fiscalYear": 2025, "totalPay": 1139142, "exercisedValue": 0, "unexercisedValue": 110613328}, {"maxAge": 1, "name": "Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D.", "age": 71, "title": "Founder, Chief Scientific Officer, Member of Executive Board & Director", "yearBorn": 1954, "fiscalYear": 2025, "totalPay": 808143, "exercisedValue": 3196231, "unexercisedValue": 60712612}, {"maxAge": 1, "name": "Mr. Mayur Amrat Somaiya", "age": 51, "title": "Chief Financial Officer", "yearBorn": 1974, "fiscalYear": 2025, "totalPay": 770393, "exercisedValue": 827723, "unexercisedValue": 10852775}, {"maxAge": 1, "name": "Mr. Douglas F. Kling", "age": 52, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2025, "totalPay": 790051, "exercisedValue": 11558026, "unexercisedValue": 12724696}, {"maxAge": 1, "name": "Ms. Louise  Kooij", "age": 49, "title": "Chief Accounting Officer", "yearBorn": 1976, "fiscalYear": 2025, "totalPay": 695419, "exercisedValue": 9576082, "unexercisedValue": 7423517}, {"maxAge": 1, "name": "Mr. Matthew  Philippe", "title": "Executive VP &Head of Investor Relations", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bob  Rambo", "title": "Executive Vice President of Marketing", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Maryellen  McQuade", "title": "Chief People Officer", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Juliette  Audet M.B.A., M.Sc.", "age": 38, "title": "Chief Strategy & Business Officer", "yearBorn": 1987, "fiscalYear": 2025, "totalPay": 653039, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marc  Ditmarsch M.D.", "age": 58, "title": "Chief Development Officer", "yearBorn": 1967, "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1767139200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 25.97, "open": 24.41, "dayLow": 25.94, "dayHigh": 25.98, "regularMarketPreviousClose": 25.97, "regularMarketOpen": 24.41, "regularMarketDayLow": 25.94, "regularMarketDayHigh": 25.98, "beta": 0.069, "volume": 601, "regularMarketVolume": 601, "averageVolume": 621, "averageVolume10days": 850, "averageDailyVolume10Day": 850, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "fiftyTwoWeekLow": 5.45, "fiftyTwoWeekHigh": 29.99, "allTimeHigh": 29.99, "allTimeLow": 0.06, "fiftyDayAverage": 22.65462, "twoHundredDayAverage": 17.30692, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "profitMargins": 0.0, "floatShares": 69227851, "bookValue": 5.974, "priceToBook": 4.347171, "netIncomeToCommon": -203819008, "52WeekChange": 1.5957446, "SandP52WeekChange": 0.11527538, "quoteType": "EQUITY", "currentPrice": 25.97, "recommendationKey": "none", "totalCash": 636241024, "totalCashPerShare": 5.534, "ebitda": -225463008, "totalDebt": 202000, "quickRatio": 7.686, "currentRatio": 7.876, "totalRevenue": 22503000, "debtToEquity": 0.03, "revenuePerShare": 0.19, "returnOnAssets": -0.17266001, "returnOnEquity": -0.2829, "grossProfits": 22503000, "freeCashflow": -112909872, "operatingCashflow": -147783008, "revenueGrowth": -0.998, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -2061.875, "financialCurrency": "USD", "symbol": "NAMSW", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "fiftyDayAverageChange": 3.31538, "fiftyDayAverageChangePercent": 0.14634456, "twoHundredDayAverageChange": 8.66308, "twoHundredDayAverageChangePercent": 0.5005559, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2022-11-23", "cryptoTradeable": false, "regularMarketChangePercent": 0.0, "regularMarketPrice": 25.97, "shortName": "NewAmsterdam Pharma Company N.V", "longName": "NewAmsterdam Pharma Company N.V.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1612967400000, "regularMarketChange": 0.0, "regularMarketDayRange": "25.94 - 25.98", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 621, "fiftyTwoWeekLowChange": 20.52, "fiftyTwoWeekLowChangePercent": 3.765138, "fiftyTwoWeekRange": "5.45 - 29.99", "fiftyTwoWeekHighChange": -4.0200005, "fiftyTwoWeekHighChangePercent": -0.13404469, "fiftyTwoWeekChangePercent": 159.57446, "corporateActions": [], "regularMarketTime": 1771428427, "exchange": "NGM", "messageBoardId": "finmb_685404834", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "displayName": "NewAmsterdam Pharma Company", "trailingPegRatio": null, "__fetch_time": "2026-02-21"}]